Evaluating a Shorter, Rifampicin-Based Treatment for People With Less Severe Tuberculosis Disease

Inclusion Criteria: 1. Aged 12 years and over 2. Clinical and/or radiological evidence of pulmonary TB 3. At least one sputum specimen positive for M. tuberculosis by Xpert MTB/RIF or Ultra within 30 days of screening confirming rifampicin-sensitive TB 4. Have limited TB disease defined as having a cycle threshold on sputum Xpert MTB/RIF or Ultra corresponding to 'medium' or below for bacterial burden at screening (where results from more than one test are available at screening, eligibility will be determined by the highest grade) 5. Documentation of HIV status from a validated test performed within 30 days of screening or known to be HIV-positive 6. Well enough to be treated as an outpatient Exclusion Criteria: 1. Received more than 7 days treatment for index TB episode 2. Previous treatment for active TB disease in past 12 months 3. M. tuberculosis with known resistance to rifampicin or isoniazid 4. Weight \< 30 kg at screening 5. Sick with one or more WHO 'danger signs' at screening (respiratory rate \> 30 breaths per minute, temperature \> 39 ˚C, heart rate \> 120 bpm, inability to walk unaided) 6. Suspected or confirmed extra-pulmonary TB involving the central nervous system, bones, joints, abdomen, and/or pericardium (coexistent pleural or lymph node TB are not exclusions) 7. For participants living with HIV: * Urinary lipoarabinomannan test positive at screening * Requires protease inhibitor-based antiretroviral therapy, and/or long acting antiretrovirals cabotegravir/rilpivirine 8. For participants of child-bearing potential: currently pregnant or not currently pregnant but unwilling to practice an effective method of contraception during study drug treatment 9. Clinical evidence of acute hepatitis or advanced chronic liver disease (e.g. jaundice, signs of portal hypertension) 10. Known end stage renal failure 11. Active malignancy not in remission or had systemic chemotherapy within 2 years (except for non-melanomatous skin cancer) 12. Contraindication to study medications because of known allergy or intolerance or unavoidable drug-drug interaction 13. Other medical conditions, that, in the investigator's judgment, make study participation not in the individual's best interest 14. Inability to attend follow up visits